This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Contents — quick navigation | ||
|---|---|---|
| A | Basic information | ICD-10: G41.9 | Special Copayment Reduction: V125 | Coverage period: 5 years |
| B | Synonyms | Status epilepticus (unspecified), status epilepticus NOS (not otherwise specified) |
| C | Adult onset | SE occurs at all ages; bimodal incidence (high in infants and the elderly); adult SE commonly has symptomatic causes such as stroke and metabolic disorders |
| S1 | History | Historical descriptions of SE, changes in definition, the ILAE 2015 classification innovation |
| S2 | Causes | Acute symptomatic, remote symptomatic, progressive, idiopathic; differences in major causes by age |
| S3 | Genetics | Spectrum of major genes associated with SE; pharmacogenomic considerations |
| S4 | General epidemiology | Annual incidence 10–41/100,000; mortality 10–22%; bimodal age distribution |
| S5 | Pathophysiology | Failure of seizure termination mechanisms; GABA internalization; glutamate overactivation; systemic complications |
| S6 | Symptoms | Clinical spectrum of convulsive SE vs nonconvulsive SE |
| S7 | Signs | EEG findings by type; signs of systemic complications |
| S8 | Screening | Emergency testing panel; necessity of EEG; tests to identify the cause |
| S9 | Diagnosis | ILAE 2015 definition; Salzburg criteria; the four axes of the ILAE classification |
| S10 | Treatment | Stepwise treatment algorithm; management of refractory and super-refractory SE |
| S11 | Prognosis | STESS and EMSE prognostic indicators; determinants of mortality and morbidity |
| S12 | Prevention | Primary and secondary prevention; home emergency medications; patient education |
| S13 | References | 10 key references |
Medical descriptions of status epilepticus (SE) date back to ancient civilizations. Babylonian medical texts (circa 700 BC) describe a state of continuous convulsions, and Hippocrates also recorded the continued occurrence of convulsions as an ominous sign. However, the modern concept of SE was formed in the 19th century.
In 1824, the French physician Louis-Florentin Calmeil first formally used the term "état de mal épileptique," and in 1876 William Richard Gowers described in detail the clinical features and natural course of SE, contributing to the recognition of SE as a neurological emergency. The introduction of EEG technology in the early 20th century made accurate diagnosis and classification of SE possible.
The definition of SE has changed historically. Until the 1960s, "a seizure lasting 30 minutes or longer" was the standard definition. This 30-minute criterion reflected the time at which neuronal injury begins in animal experiments. However, clinical epidemiological studies confirmed that tonic-clonic seizures lasting 5 minutes or longer very rarely terminate spontaneously, so a 5-minute criterion was introduced as a practical time to start treatment.
In 2015, the ILAE Task Force published a comprehensive definition and classification of SE. This classification introduced a four-axis system: (1) classification by seizure type, (2) classification by etiology, (3) classification by EEG correlates and (4) classification by age. It also supported clinical decision-making by setting two time criteria (T1: start of treatment, T2: effect on long-term outcome) for each seizure type. This classification system is still used as the international standard for clinical research and practice in SE.
Increased recognition of nonconvulsive SE (NCSE) came along with advances in continuous EEG monitoring technology beginning in the 1990s. The development of the Salzburg EEG criteria in 2013 contributed to standardizing the diagnosis of NCSE, and several subsequent studies validated the sensitivity (97.7%) and specificity (89.6%) of these criteria.
The causes of SE are broadly classified as acute symptomatic, remote symptomatic, progressive, and idiopathic/cryptogenic.
| Age group | Major causes |
|---|---|
| Neonates (0–28 days) | Hypoxic-ischemic encephalopathy, hypoglycemia, hypocalcemia, intracranial hemorrhage, inborn errors of metabolism, meningitis |
| Infants (1–12 months) | Infantile spasms (West syndrome), febrile seizures, encephalitis, congenital brain structural abnormalities |
| Children (1–12 years) | Febrile status epilepticus, exacerbation of underlying epilepsy (such as LGS), encephalitis, head trauma |
| Adolescents/adults (13–60 years) | Discontinuation of antiseizure medication, autoimmune encephalitis, brain tumor, alcohol-related, head trauma |
| Elderly (>60 years) | Stroke, dementia, metabolic abnormalities (hypoglycemia, hyponatremia), drug toxicity, neurodegenerative diseases |
SE is not a single genetic disease, but genetic predisposition has an important influence on susceptibility to SE.
| Gene | Associated disease | SE type |
|---|---|---|
| SCN1A | Dravet syndrome, GEFS+ | Febrile tonic-clonic SE, fever-triggered |
| POLG1 | Alpers syndrome | Refractory myoclonic SE; valproate contraindicated |
| TSC1/TSC2 | Tuberous sclerosis | Infantile spasms, SE associated with LGS |
| CDKL5 | CDKL5 deficiency disorder | Early-onset refractory SE |
| STXBP1 | Ohtahara syndrome | Neonatal SE, early infantile SE |
| GRIN2A | Sleep-related epilepsy | Frontal lobe SE during sleep |
| EPM2A/NHLRC1 | Lafora body disease | Progressive myoclonic SE |
CYP2C9/CYP2C19 polymorphisms affect the metabolism of phenytoin and valproate and are relevant to predicting serum concentrations and adjusting doses. HLA-B*15:01/HLA-A*31:01 testing is used to prevent carbamazepine-associated severe cutaneous reactions. Such pharmacogenomic information is becoming increasingly important for optimizing SE treatment.
SE is one of the most common neurological emergencies. Pooling large epidemiological studies from the United States and Europe, the annual incidence is reported as 10–41 per 100,000 population. In the United States, about 150,000 cases of SE occur annually, of which about 42,000 patients are estimated to die.
The incidence of SE is markedly higher in infancy (under 1 year of age) and old age (60 years and older). The main causes of SE in infancy are febrile SE, congenital brain structural abnormalities and inborn errors of metabolism, and the main causes of SE in old age are stroke, metabolic abnormalities and dementia-related seizures.
In university hospital–based studies in Korea, the annual incidence of SE is reported to be at a level similar to that of Western countries, and with entry into an aging society, the proportion of post-stroke SE and SE of metabolic cause is increasing.
The pathophysiology of SE can be summarized as failure of the normal seizure termination mechanisms. Normally, seizures terminate spontaneously through mechanisms such as strengthening of GABA-ergic inhibition, neuronal fatigue and synaptic depletion. In SE, these termination mechanisms fail, or the seizure persists in a self-sustaining manner because of a pathological state.
Early SE (0–30 minutes): autonomic nervous system overactivation raises blood pressure, heart rate and blood glucose. Late SE (>30 minutes): elevated body temperature from muscle activity, lactic acidosis, myoglobinuria and kidney failure due to rhabdomyolysis, respiratory depression and pulmonary aspiration, and decreased blood glucose occur, worsening brain injury.
The clinical symptoms of SE differ greatly depending on seizure type. G41.9 (unspecified) is a code used when the type is difficult to classify clearly or as a temporary code before the final type classification.
Generalized tonic-clonic convulsions lasting 5 minutes or longer, or repeated seizures without recovery of consciousness between them. It is the type that is clinically easiest to recognize.
A state of persistent impairment of consciousness without convulsions, which is difficult to recognize clinically. It includes absence SE (ASE), complex partial SE (CPSE), subtle SE and electrographic-only SE. NCSE should always be differentiated in patients with unexplained impaired consciousness in the emergency department or intensive care unit.
| EEG pattern | Features | Clinical significance |
|---|---|---|
| Continuous seizure discharges | Monotonous or complex rhythmic discharges; >10 seconds | Convulsive or nonconvulsive SE |
| Intermittent seizure discharges | Alternation of seizure discharges and suppression | Possible nonconvulsive SE; judged according to context |
| Burst-suppression pattern | Alternation of high-amplitude bursts and electrical silence | Severe brain injury; anesthesia-induced state |
| Periodic discharges (LPD, GPD) | Lateralized/generalized periodic discharges | Located at the boundary between SE and interictal abnormality |
In patients with suspected or confirmed SE, the following screening tests are performed immediately.
Status epilepticus (SE) is defined as "a condition resulting from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms that lead to abnormally prolonged seizures (persisting beyond time point T1)." In convulsive SE, T1 (the criterion for starting treatment) is 5 minutes, and T2 (the point at which long-term damage is possible) is 30 minutes.
Salzburg EEG criteria for the diagnosis of nonconvulsive SE (2013):
In doubtful cases, a trial administration of a benzodiazepine (a small dose of lorazepam) with simultaneous confirmation of EEG improvement and clinical response can be used as a diagnostic aid.
SE treatment follows a staged protocol. If there is no response to treatment at each stage, proceed promptly to the next stage.
Immediate measures (0 minutes): Secure ABCs (airway, breathing, circulation), administer oxygen, establish IV access, measure and correct blood glucose, monitor vital signs, attach EEG (if possible)
Stage 1 — Initial treatment (within 5 minutes): Lorazepam IV 0.1 mg/kg (max 4 mg) / midazolam IM 0.2 mg/kg (max 10 mg) / diazepam rectal 0.2–0.5 mg/kg
Stage 2 — Second-line drugs (20–40 minutes): Fosphenytoin 20 mg PE/kg IV (maximum 150 mg PE/min) / valproate 30–40 mg/kg IV (contraindicated if POLG disease is suspected) / levetiracetam 60 mg/kg IV (max 4,500 mg) / lacosamide 200–400 mg IV (especially consider in focal SE)
Stage 3 — Refractory SE (30–60 minutes): Midazolam continuous infusion 0.05–0.4 mg/kg/h / propofol 1–2 mg/kg loading followed by 1–5 mg/kg/h (adults, within 48 hours) / phenobarbital 15–20 mg/kg IV / ICU admission and cEEG monitoring
Stage 4 — Super-refractory SE (>24–48 hours): Ketamine (NMDA receptor antagonist) / inhalational anesthetic (isoflurane) / ketogenic diet / immunotherapy (autoimmune cause) / hypothermia therapy / neurosurgery (focal lesion)
| Situation | Specific treatment |
|---|---|
| Hypoglycemic SE | 50% glucose 50 mL IV; thiamine 100 mg IV (in alcohol-dependent patients) |
| Isoniazid toxicity | Pyridoxine (vitamin B6) 5 g IV |
| Eclampsia in pregnancy | Magnesium sulfate IV; delivery planned after the mechanism occurs |
| POLG-related SE | Valproate contraindicated; choose levetiracetam or lacosamide |
| Autoimmune SE | IV immunoglobulin, steroids, plasma exchange; consider rituximab |
The prognosis of SE is determined by multiple factors, including the underlying disease, duration of SE, patient age and promptness of treatment.
| Factor | Effect |
|---|---|
| Underlying disease | Worse in the order of acute symptomatic (stroke, hypoxia) > remote symptomatic > idiopathic |
| Duration of SE | >30 minutes: increased risk of neuronal injury; >2 hours: poor prognosis |
| Patient age | The older the patient, the higher the mortality; pediatric febrile SE is relatively favorable |
| Promptness of treatment | Outcomes improve when treatment is started within 5 minutes |
| Refractoriness | Refractory SE (RSE): mortality 15–25%; super-refractory (SRSE): >30% |
In long-term follow-up of SE survivors, new-onset epilepsy (symptomatic epilepsy), cognitive decline and reduced quality of life are observed. A long-term follow-up study (FEBSTAT study) on the possibility of developing temporal lobe epilepsy after febrile status epilepticus is under way.